Share

CLINICAL TRIAL SEARCH RESULTS

NEW SEARCH
 Number: 201103308 Principal Investigator: Linette, Gerald
Title: Mature Dendritic Vaccination Against gp100 in Patients with Advanced Melanoma
Description: You may be asked to participate in this study because you have been diagnosed with metastatic melanoma. Although there are treatments that can control your disease for a period of time, there are no treatments that have been shown to cure melanoma once it has spread to distant sites in the body (su...MORE
___________________________________________________________________________________________________
 Number: CTSU E1609 Principal Investigator: Linette, Gerald
Title: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a- 2b for Resected High-Risk Melanoma
Description: The purpose of this study is to compare the effects, good and/or bad, of ipilimumab with interferon alfa-2b on patients and their melanoma to find out which is better....MORE
___________________________________________________________________________________________________
 Number: CALGB N0879 Principal Investigator: Linette, Gerald
Title: A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma (N0879)
Description: There are two purposes of this research study. They are: Find out what effects (good and bad) the combination of study drugs has on patients and their melanoma Find out what effects the combination of study drugs has on each patient's immune system and the way their tumor grows...MORE
___________________________________________________________________________________________________
 Number: 201306025 Principal Investigator: Linette, Gerald
Title: Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination with Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Description: The purpose of this study is to test what doses of the GSK study medications dabrafenib with or without trametinib can be given safely in combination with ipilimumab....MORE
___________________________________________________________________________________________________
 Number: 201211017 Principal Investigator: Linette, Gerald
Title: A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutaneous melanoma
Description: In this study we will compare Pimasertib to Dacarbazine. The primary research study goal is to compare the length of time, during and after treatment, in which patients can live without their disease getting worse. Additional purposes of the study are to find out about the side effects of Pimaserti...MORE
___________________________________________________________________________________________________
 Number: 201209116 Principal Investigator: Linette, Gerald
Title: A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib versus Vemurafenib Plus Gdc-0973 in Previously Untreated BRAFV600-Mutation Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma
Description: The purpose of this study is to compare the effects, good and/or bad, of GDC-0973 and vemurafenib with vemurafenib alone on patients and their melanoma, to find out which is better....MORE
___________________________________________________________________________________________________
 Number: 201206092 Principal Investigator: Linette, Gerald
Title: A Phase I/II, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination with an Oral Activator Ligand, in Subjects with Unresectable Stage III or IV Melanoma
Description: The main purpose of this study is to evaluate the safety and tolerability of tumor injections of INXN-2001 given in combination with different doses of INXN-1001 for patients with unresectable stage III or IV melanoma....MORE
___________________________________________________________________________________________________
 Number: 201205056 Principal Investigator: Linette, Gerald
Title: A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence
Description: The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients have undergone surgery....MORE
___________________________________________________________________________________________________
 Number: 201204076 Principal Investigator: Linette, Gerald
Title: An Open-Label, Multicenter, Phase II Study of Continuous Oral Vemurafenib in Patients with Locally Advanced, Unresectable, Stage IIIC or Metastatic Melanoma and Activating Exon 15 BRAF Mutations other than V600E
Description: The purpose of this study is to assess the potential side effects and effectiveness of vemurafenib as an investigational drug for the treatment of metastatic melanoma in patients with other than BRAF V600E mutations....MORE
___________________________________________________________________________________________________
 Number: 201010741 Principal Investigator: Linette, Gerald
Title: Phase I/II study to assess the safety and activity of enhanced TCR transduced autologous T cells against cancer-testis antigens in metastatic melanoma
Description: The purpose of this clinical trial is to assess the effects (both good and bad) of chemotherapy and treatment with modified T cells on cancer and general health....MORE
___________________________________________________________________________________________________
 Number: 201211040 Principal Investigator: Linette, Gerald
Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients with Surgically Resected, Cutaneous BRAF-Mutant Melanoma at High Risk for Recurrence
Description: The purpose of this study is to find out whether vemurafenib can help prevent or delay the return of melanoma that is at a high risk of returning (Stage IIC, IIIA, IIIB or IIIC) after it has been removed surgically. The study will also assess whether the drug causes side effects in patients....MORE
___________________________________________________________________________________________________
 Number: 201109292 Principal Investigator: Cornelius, Lynn
Title: Tissue Acquisition for Analysis of Genetic Factors in Melanoma and Other Skin Cancers
___________________________________________________________________________________________________
 Number: 201105020 Principal Investigator: Anadkat, Milan
Title: Retrospective and Prospective Data Collection and Analysis of Cutaneous Chemotherapy REACTions at Washington University
___________________________________________________________________________________________________